Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.

Jonathan BarrattWladyslaw SulowiczMichael SchömigCiro EspositoMichael ReuschJames YoungBotond Csiky

Published in: Advances in therapy (2021)

Roxadustat improved hemoglobin similarly to ESA while demonstrating comparable cardiovascular and overall safety profiles in a wide spectrum of dialysis-dependent patients with anemia of CKD. Roxadustat represents an oral alternative to ESAs for achieving a target hemoglobin for anemia of CKD in dialysis-dependent patients.

Keyphrases

chronic kidney disease
end stage renal disease
peritoneal dialysis
clinical trial
newly diagnosed
double blind